Voluntary ex ante transparency notice
Directive 2014/24/EU
Section I: Contracting
entity
I.1) Name and addresses
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
2nd Floor Woodland House
Cardiff
CF14 4TT
UK
Contact person: Ryan James
Telephone: +44 1443848585
E-mail: ryan.james3@wales.nhs.uk
NUTS: UK
Internet address(es)
Main address: http://nwssp.nhs.wales/ourservices/procurement-services/
Address of the buyer profile: https://www.sell2wales.gov.wales/search/Search_AuthProfile.aspx?ID=AA0221
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Provision of WES Trio and Singleton Virtual Panel Analysis for Welsh Patients
Reference number: CAV-STA (2021/2022) 11
II.1.2) Main CPV code
71900000
II.1.3) Type of contract
Services
II.1.4) Short description
In-line with All Wales Medical Genomic Service’s (AWMGS) commissioning model, AWMGS will procure from CeGaT whole exom sequencing (WES) for trio or singleton virtual panel analysis for patients where this testing cannot be accessed within the NHS E laboratory network. This genetic testing will ensure equity of access to genomic testing for Welsh patients and meet their need to seek a timely genetic diagnosis for their rare or inherited disease.
II.1.6) Information about lots
This contract is divided into lots:
No
II.1.7) Total value of the procurement
Value excluding VAT:
275 000.00
GBP
II.2) Description
II.2.3) Place of performance
NUTS code:
UKL22
Main site or place of performance:
All Wales Medical Genomics Service, Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW
II.2.4) Description of the procurement
NWSSP Procurement Services intends to award a contract on behalf of Cardiff and Vale University Health Board, AWMGS, for the supply of WES single and trio based testing from CeGAT. The contract is estimated to commence in July 2021, for a period of two years. The first year’s delivery will be capped at 175,000 GBP and reviewed to ensure that value for money is being achieved through the pick-up rate of pathogenic findings as a means of ensuring appropriate referrals and use of this bespoke service. The second year’s service will be capped at estimated 100,000 GBP assuming AWMGS are able to deliver in-house WES-based testing for Welsh patients within 2022/23 as currently planned.
II.2.11) Information about options
Options:
No
II.2.13) Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds:
No
Section IV: Procedure
IV.1) Description
IV.1.1) Type of procedure
Award of a contract without prior publication of a call for competition
Justification for selected award procedure:
The procurement falls outside the scope of application of the Directive
Explanation:
All Wales Genomics Service (AWMGS) is commissioned by the Wealth Health Specialist Services Commission (WHSSC) to provide genetic testing for Welsh patients which is equitable to the provision NHS E makes available through the Rare and Inherited Disease Test Directory. NHS E patients can currently access a range of Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) tests for rare and inheritable diseases which the laboratory is unable to deliver in-house. In-house service developments are ongoing to enable the delivery of equivalent genetic tests but these will not go-live until 2022 – 24 (services will be introduced over a 18-24 month basis).
Where feasible, AWMGS commission genetic tests from within the NHS network for Welsh patients. NHS E genetic laboratories currently provide Welsh patients with access to a small number of trio WES-based tests, e.g. Exeter genetic laboratory provides and a larger number of phenotype driven singleton virtual panel tests. Importantly, WGS based testing is not available at all to AWMGS patients from NHS E laboratories due to the centralised model developed by Genetics England.
AWMGS will procure from CeGaT WES for trio or singleton virtual panel analysis for patients where this testing cannot be accessed within the NHS E laboratory network. For Single Exome Diagnostics, CeGaT will analyse a virtual panel of genes that are known to be associated with the patient’s phenotype. The virtual panel will be selected from a list of panels that have been curated by the NHS Genomic Medicine Service and are aligned to the NHSE Test Directory. These panels can be found at https://panelapp.genomicsengland.co.uk/
Targeted analysis of the ACMG genes is NOT requested for any samples received from AWMGS.
Should incidental or secondary findings be identified through routine analysis and not as part of a targeted analysis, these may reported to the referring clinician depending on the preference of the patient that will be indicated on the customised referral form that has been designed to meet the needs of the AWMGS service.
There is no alternative supplier within Europe providing an equivalent customised WES trio or singleton service to CeGAT which delivers against PanelApp green gene lists. Through procuring this specialist service from CeGAT AWMGS will ensure equity of access to genetic testing across NHS E and NHS W patient cohort in line with the commissioning model agreed with WHSSC.
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
Yes
Section V: Award of contract/concession
Contract No: CAV-STA (2021/2022) 11
V.2 Award of contract/concession
V.2.1) Date of conclusion of the contract/concession
11/06/2021
V.2.2) Information about tenders
The contract has been awarded to a group of economic operators:
No
V.2.3) Name and address of the contractor
CeGaT GmbH
Paul-Ehrlich-Straße 23
Tubingen
D72076
DE
Telephone: +44 7500081932
NUTS: DE1
The contractor is an SME:
No
V.2.4) Information on value of the concession and main financing terms (excluding VAT)
Total value of the concession/lot:
275 000.00
GBP
V.2.5) Information about subcontracting
Section VI: Complementary information
VI.3) Additional information
NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=111599.
(WA Ref:111599)
VI.4) Procedures for review
VI.4.1) Review body
High Court
Royal Courts of Justice, The Strand
London
WC2A 2LL
UK
Telephone: +44 2079477501
VI.4.3) Review procedure
Precise information on deadline(s) for review procedures:
The Authority will allow a minimum 10 calendar day standstill period between notifying the award decision and awarding the contract. Should additional information be required from the addressee in section 1.1 Ryan James (ryan.james3@wales.nhs.uk).
The Contracting Authority will enter into this Contract following a minimum 10 day calendar day standstill period starting on the day after this notice is published onFind a Tender. If legal proceedings are commenced in relation to the contract award, it will be necessary to suspend the award of the contract pending further order of the Court, or the authority may voluntarily decide (at its discretion) to suspend the award of contract whilst any outstanding queries are dealt with. We will not be liable for any costs or losses incurred by you as a result of any suspension of the contract award or as a result of any other action made necessary by any challenge.
VI.5) Date of dispatch of this notice
24/06/2021